Glonghui, May 30, 丨 Goldman Sachs Research Report said that Alibaba Health (0241.HK)'s revenue for the 2023 fiscal year ending March increased 30% year-on-year to 26.8 billion yuan, which is generally in line with expectations. Under the Hong Kong Financial Reporting Standards (HKFRS), it turned a loss into a profit and recorded a net profit of 534 million yuan, which is in line with expectations. The bank lowered Ali Health's revenue growth forecast for fiscal year 2024 to 17%, and the net profit margin remained at around 2.5%. It is also expected to gradually expand to about 3.5% in 2026. The original forecast was 2.9%. Maintaining its “neutral” rating, the target price was lowered from HK$6.7 to HK$6.4. The stock is currently reported at HK$4.75, with a total market value of HK$64.2 billion.